Prosecution Insights
Last updated: April 19, 2026

Examiner: SIFFORD, JEFFREY MARK

Tech Center 1600 • Art Units: 1648 1671

This examiner grants 60% of resolved cases

Performance Statistics

59.8%
Allow Rate
At TC average
120
Total Applications
+30.2%
Interview Lift
1194
Avg Prosecution Days
Based on 82 resolved cases, 2023–2026

Rejection Statute Breakdown

5.8%
§101 Eligibility
16.3%
§102 Novelty
32.4%
§103 Obviousness
31.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17622044 ADENO-ASSOCIATED VIRUS PURIFICATION METHODS Non-Final OA TAKEDA PHARMACEUTICAL COMPANY LIMITED
18151174 NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18022056 ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS Non-Final OA California Institute of Technology
17919997 COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES Non-Final OA DUKE UNIVERSITY
18087173 VIRUS SEPARATION Final Rejection Cytiva US LLC
18817094 Rhinovirus Vaccine Non-Final OA IP2IPO INNOVATIONS LIMITED
17791981 SYSTEM AND METHOD FOR PROCESSING VIRUS PREPARATIONS TO REDUCE HETEROGENEITY Non-Final OA THE TRUSTEES OF INDIANA UNIVERSITY
17911367 KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME Non-Final OA Wisconsin Alumni Research Foundation
18345478 ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF Non-Final OA The United States of America, As Represented by the Secretary, Dept. of Health and Human Services
17767532 PRODUCTION METHOD AND DETECTION METHOD OF AFRICAN SWINE FEVER VIRUS Final Rejection National Agriculture and Food Research Organization
17919065 ADENOVIRUS IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT Final Rejection Denka Company Limited
17615961 MDBK IRF3/IRF7 KNOCK OUT MUTANT CELL AND ITS USE FOR VACCINE PRODUCTION Non-Final OA Intervet Inc.
17263490 ENGINERRED ANTIBODIES TO HIV ENV Non-Final OA The Scripps Research Institute
17948868 DUAL BIFUNCTIONAL VECTORS FOR AAV PRODUCTION Final Rejection uniQure biopharma B.V.
18000638 CHIMERIC ADENOVIRAL VECTORS Non-Final OA Vaxart, Inc.
17416810 NOROVIRUS VACCINE FORMULATIONS AND METHODS Non-Final OA TAKEDA VACCINES, INC.
17274016 DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF Final Rejection Takeda Vaccines, Inc.
17777112 VIRAL INACTIVATION METHOD, METHOD FOR PRODUCING DRIED AMNION, AND DRIED AMNION Final Rejection SAKURA SEIKI CO., LTD.
17633063 CELLULAR COMPOSITIONS COMPRISING VIRAL VECTORS AND METHODS OF TREATMENT Final Rejection Mesoblast International Sárl
18007441 BACTERIOPHAGE, BACTERIAL WILT DISEASE CONTROL AGENT, AND BACTERIAL WILT DISEASE CONTROL METHOD Non-Final OA PANEFRI INDUSTRIAL CO., LTD.
18007823 ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA Non-Final OA Sartorius BIA Separations d.o.o.
18011742 METHOD FOR PREPARING ADENOVIRUS VECTOR VACCINE BY MEANS OF PERFUSION CULTURE PROCESS Non-Final OA CANSINO BIOLOGICS INC.
18058403 ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2 Non-Final OA ARABIAN GULF UNIVERSITY
17736181 ENGINEERED BACTERIOPHAGE T4 NANOPARTICLES AS A POTENTIAL TARGETED ACTIVATOR OF HIV-1 LATENCY IN CD4+ HUMAN T-CELLS Final Rejection The Catholic University of America
17767195 siRNA EXPRESSION VECTOR Final Rejection TAKARA BIO INC.
17627162 USE OF ION CONCENTRATIONS TO INCREASE THE PACKAGING EFFICIENCY OF RECOMBINANT ADENO-ASSOCIATED VIRUS Final Rejection CHARLES RIVER LABORATORIES, INC.
17605524 New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy Final Rejection Universite Paris XIII Paris-Nord Villetaneuse
17180351 Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies Non-Final OA Anubis Bio Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month